Tumor-specific diagnosis of F-18 FBPA PET / CT

Phase 2

• Conditions: Patients with lesions that are difficult to distinguish between tumor and inflammation; tumor, inflammation

• Registration Number: JPRN-jRCTs051190116
• Lead Sponsor: Ono Koji

Brief Summary

The results of this study showed that F-18 FBPA PET/CT was superior to 18F-FDG PET/CT for differential diagnosis of malignant tumors andbenign lesions. There are some limitations due to low F-18 FBPA accumulation in certain tumors, but the additional information obtained from F-18 FBPA PET/CT can reduce false positives from F-18 FDG PET/CT in tumor diagnosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-04
• Study Completion: 2022-04-18
• Results First Posted: 2022-12-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Patients with lesions that are difficult to distinguish between tumor and inflammation

Exclusion Criteria

Pregnant women or those who wish to become pregnant
Under 20 years of age
A person who is determined to be unsuitable for participation in this study by the researcher or researcher

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SUV value (SUV max, SUV mean) of target lesions obtained with F-18 FBPA PET / CT<br>Pathological diagnosis (benign/ malignant judgment)

Secondary Outcome Measures

Name	Time	Method
Radioactivity ratio between the target lesion and the left ventricular blood pool obtained with F-18 FBPA PET / CT (Lesion / Blood ratio)<br>Radioactivity ratio (Lesion / Normal ratio) between target lesions and contralateral normal tissues obtained with F-18 FBPA PET / CT<br>Radioactivity ratio between blood radioactivity and blood pool in the left ventricular calculated from F-18 FBPA PET / CT images<br>The above items are evaluated and analyzed for each patient.